LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance

Anne Berberich, Frederik Bartels, Zili Tang, Maximilian Knoll, S Pusch, Nanina Hucke, Tobias Keßler, Zhen Dong, Benedikt Wiestler, Frank Winkler, Michael Platten, Wolfgang Wick, Amir Abdollahi, Dieter LemkeFrontiers in Oncology 2020 · DOI

TL;DR

This study reveals a critical crosstalk between LAPTM5 and CD40 in glioblastoma, showing that LAPTM5 acts as a tumor suppressor by inhibiting CD40-mediated NF-κB signaling. This interaction is key to glioblastoma invasion and resistance to temozolomide, suggesting LAPTM5 could be a biomarker for predicting treatment response in CD40-positive tumors.

What Problem Does This Paper Address?

Glioblastoma, a highly aggressive brain tumor, is notoriously difficult to treat due to its diffuse, invasive growth and resistance to standard therapies like temozolomide. While the molecular mechanisms driving invasion and resistance are complex, understanding specific molecular interactions that promote or inhibit these processes is crucial for developing more effective treatments. This paper focuses on Lysosomal Protein Transmembrane 5 (LAPTM5), identified as an invasion inhibitor, and its potential interaction with the CD40 receptor, a known target in cancer immunotherapy, to understand their combined role in glioblastoma's aggressive behavior.

Methods

The researchers employed a multi-pronged approach:

  • Gene Knockdown and Overexpression: They used lentiviral shRNAs to reduce LAPTM5 and CD40 expression (knockdown) in various glioblastoma cell lines. Conversely, they used plasmids to overexpress CD40 in cells where it was naturally low.
  • Functional Assays: Standard assays were used to assess the impact of these genetic manipulations on:
  • Clonogenicity: The ability of cells to form colonies (Limiting Dilution Assay).
  • Invasiveness: The capacity of cells to migrate through a matrix (Matrigel Invasion Assay).
  • Tumorigenicity: Tumor formation and growth in vivo (Xenograft Mouse Model).
  • Chemosensitivity: Response to temozolomide treatment.
  • Molecular Pathway Analysis:
    • Expression Arrays (Microarray/RNASeq): To identify underlying gene expression changes and pathways affected by LAPTM5 knockdown.
  • Western Blotting: To detect protein levels and activation states, particularly for the NF-κB pathway.
  • Flow Cytometry: To quantify cell surface expression of CD40.
  • Bioinformatic Analysis:
    • TCGA Data Analysis: To correlate LAPTM5 and CD40 expression with clinical outcomes (survival) in a large cohort of glioblastoma patients.
  • CIBERSORT: To estimate immune cell infiltration in tumors.

Datasets

The study utilized several datasets:

  • Glioblastoma Cell Lines: A panel of established glioblastoma cell lines (LN-229, LN-308, U-87MG, LN-428, T98G) and primary glioblastoma-initiating cells were used for in vitro experiments.
  • Xenograft Mouse Model: Immunocompromised mice were used for in vivo tumor growth studies.
  • The Cancer Genome Atlas (TCGA): Methylation array and RNASeq data from the TCGA-GBM cohort were used for clinical correlation and survival analysis.

Key Insights and Ideas

  • LAPTM5 is a tumor suppressor in glioblastoma: The study provides strong evidence that LAPTM5 actively inhibits glioblastoma cell proliferation, invasion, and overall tumorigenicity.
  • CD40 is essential for LAPTM5's tumor-suppressive function: LAPTM5's ability to inhibit invasion and clonogenicity is almost entirely dependent on the presence of CD40. Without CD40, LAPTM5 has little to no effect.
  • LAPTM5 inhibits NF-κB signaling via CD40: The core mechanism identified is that LAPTM5 acts as a negative regulator of CD40-mediated NF-κB activation. When LAPTM5 is present, it dampens this pathway; when LAPTM5 is knocked down, CD40 signaling leads to increased NF-κB activity, promoting aggressive tumor behavior.
  • LAPTM5 sensitizes glioblastoma to temozolomide: In CD40-positive glioblastoma cells, LAPTM5 expression makes them more susceptible to temozolomide. Conversely, LAPTM5 knockdown leads to resistance.
  • LAPTM5 is a potential biomarker for temozolomide response: The study's clinical correlation analysis suggests that LAPTM5 expression, particularly in conjunction with CD40 status, can predict patient survival, highlighting its potential as a predictive biomarker.

Key Results

  • Inhibition of Tumorigenicity: Knockdown of LAPTM5 in CD40-positive U87MG cells significantly increased their invasiveness (3-fold) and clonogenicity.
  • CD40 Dependency: In CD40-negative cell lines (LN229, T98G), LAPTM5 knockdown had minimal impact on clonogenicity and invasiveness. However, overexpressing CD40 in these cells restored the pro-tumorigenic phenotype observed in LAPTM5-knockdown cells.
  • NF-κB Pathway Activation: LAPTM5 knockdown in U87MG cells led to increased NF-κB pathway activation, evidenced by higher p-IκB levels. This activation was abolished upon simultaneous CD40 knockdown.
  • Temozolomide Sensitivity: LAPTM5-expressing U87MG cells were significantly more sensitive to temozolomide (68% clonogenicity reduction) compared to LAPTM5-knockdown cells (23% reduction).
  • In Vivo Efficacy: LAPTM5 knockdown tumors grew faster and showed recurrence after temozolomide treatment, while LAPTM5-expressing tumors were effectively controlled by temozolomide.
  • Clinical Correlation: In the TCGA-GBM cohort, high LAPTM5 expression was associated with better overall survival in patients with CD40-high glioblastomas, but not in CD40-low tumors.

Limitations and Future Work

  • Cell Culture Artifacts: The study acknowledges that only U87MG cells showed significant CD40 surface expression in vitro, while primary glioblastoma cells and other lines did not. This might be due to cell culture conditions, but the authors note that tumor tissue data suggests CD40 signaling is relevant for a large subgroup of patients.
  • Immune Cell Signatures: While the study explored immune cell signatures, they found that M2-polarized macrophages were associated with worse prognosis in CD40-high tumors, suggesting the positive prognostic value of CD40/LAPTM5 is more likely attributed to tumor tissue rather than immune cell infiltration.
  • Future Directions: The authors propose that LAPTM5 expression status could serve as a biomarker for predicting response to temozolomide in CD40-positive glioblastomas, warranting further clinical evaluation. They also suggest that targeting the CD40 pathway in glioblastoma might require careful consideration of LAPTM5 expression, as enhancing CD40 signaling in LAPTM5-negative tumors could potentially promote aggressiveness.

Summary updated

Abstract

<b>Background:</b> Glioma therapy is challenged by the diffuse and invasive growth of glioma. Lysosomal protein transmembrane 5 (<i>LAPTM5</i>) was identified as an invasion inhibitor by an <i>in vivo</i> screen for invasion-associated genes. The aim of this study was to decipher the function of <i>LAPTM5</i> in glioblastoma and its interaction with the CD40 receptor which is intensively evaluated as a target in the therapy of diverse cancers including glioma. <b>Methods:</b> Knockdown of <i>LAPTM5</i> was performed in different glioma cell lines to analyze the impact on clonogenicity, invasiveness, sensitivity to temozolomide chemotherapy, and tumorigenicity <i>in vitro</i> and <i>in vivo</i>. An expression array was used to elucidate the underlying pathways. CD40 knockdown and overexpression were induced to investigate a potential crosstalk of <i>LAPTM5</i> and CD40. <i>LAPTM5</i> and CD40 were correlated with the clinical outcome of glioma patients. <b>Results:</b> Knockdown of <i>LAPTM5</i> unleashed CD40-mediated NFκB activation, resulting in enhanced invasiveness, clonogenicity, and temozolomide resistance that was overcome by NFκB inhibition. <i>LAPTM5</i> expression correlated with better overall survival in glioblastoma patients depending on CD40 expression status. <b>Conclusion:</b> We conclude that <i>LAPTM5</i> conveyed tumor suppression and temozolomide sensitation in CD40-positive glioblastoma through the inhibition of CD40-mediated NFκB activation. Hence, <i>LAPTM5</i> may provide a potential biomarker for sensitivity to temozolomide in CD40-positive glioblastoma.
BibTeX
@inproceedings{berberich2020laptm,
  author = {Anne Berberich and Frederik Bartels and Zili Tang and Maximilian Knoll and S Pusch and Nanina Hucke and Tobias Keßler and Zhen Dong and Benedikt Wiestler and Frank Winkler and Michael Platten and Wolfgang Wick and Amir Abdollahi and Dieter Lemke},
  title = {{LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.00747},
}
Figure